Genomic analyses of tumor and healthy tissue from patients with mantle cell lymphomas that fail to respond to treatment with the anticancer drug ibrutinib (Imbruvica) or initially respond but then stop responding and progress, provided explanations for these two types of drug resistance and suggested ways to overcome them in the clinic, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.
"Ibrutinib, a drug that targets a protein called BTK, shows unprecedented clinical activity against mantle cell lymphoma," said Selina Chen-Kiang, PhD, professor of pathology and laboratory medicine and professor of microbiology and immunology at Weill Cornell Medical College, New York. "However, the drug doesn't work for about 32 percent of patients, and their lymphomas are said to have primary resistance to ibrutinib. We are also learning that most patients whose lymphomas respond to ibrutinib eventually relapse because their tumors acquire resistance to the drug.
"The knowledge that we gained from longitudinal RNA and genomic sequencing of mantle cell lymphomas with primary and acquired resistance to ibrutinib allowed us to identify rational drug combinations that may overcome resistance in these two settings," continued Chen-Kiang. "We recently opened a clinical trial to test one of these combinations, the selective CDK4/6 inhibitor palbociclib and ibrutinib [NCT02159755]."
"Unfortunately, only a subset of mantle cell lymphoma patients respond to ibrutinib and those who do respond eventually relapse," said Lewis C. Cantley, PhD, who directs the Sandra and Edward Meyer Cancer Center at Weill Cornell. "In this paper, the authors conducted a longitudinal study to investigate molecular events that occur during treatment with ibrutinib and identified a mutation in the target of ibrutinib, BTK, that confers resistance to the drug. They also discovered that high levels of PI3K-AKT and CDK4 signaling could explain innate resistance to ibrutinib and showed in ex-vivo studies that a combination of a CDK4 inhibitor and a PI3K inhibitor might be effective for treating patients who do not respond to ibrutinib.
"This study not only suggests new approaches for treating mantle cell lymphoma but also has implications for treatment of other B cell lymphomas, such as CLL, and a diverse group of non-Hodgkin lymphomas," continued Cantley, who is also co-editor-in-chief of Cancer Discovery. Cantley recused himself from the peer review of the study.
Chen-Kiang and colleagues used whole-exome and whole-transcriptome analysis of five serial biopsies from a patient who had mantle cell lymphoma that initially responded to ibrutinib before progressing to identify reasons why mantle cell lymphomas acquire resistance to ibrutinib. After comparing these data with results from analysis of healthy tissues from the same patient, the researchers found that a mutation in BTK, the C481S mutation, appeared at relapse. The same mutation was detected at relapse in a second patient who had mantle cell lymphoma with acquired resistance to ibrutinib but not in any patients with primary resistance to the drug.
Further analyses revealed the consequences of the relapse-specific BTK C481S mutation, including activation of the PI3K and CDK4 signaling pathways, which promote cell survival and proliferation. Blocking CDK4 with the investigational anticancer drug palbociclib made ibrutinib-resistant lymphoma cells carrying the BTK C481S mutation sensitive to investigational drugs that inhibit PI3K. In addition, palbociclib made ibrutinib-resistant lymphoma cells harboring normal BTK sensitive to both ibrutinib and investigational drugs that inhibit PI3K.
"We are very excited to have generated data that we have been able to put together in a way that may be meaningful for patients," said Chen-Kiang. "It is also exciting because CDK4 is a new kind of drug target; it controls the cell cycle, which is a central cancer pathway. As such, it is not just important for mantle cell lymphoma but for many forms of cancer."
This study was supported by funds from the Lymphoma Research Foundation, the Lymphoma Foundation, the Cancer Research and Treatment Fund, the Leukemia and Lymphoma Society, and the National Cancer Institute. Chen-Kiang declares no conflicts of interest.
Explore further: Study identifies rational drug combinations that may overcome mantle cell lymphoma resistance to ibrutinib
Medical Xpress on facebook
Related Stories
Study identifies rational drug combinations that may overcome mantle cell lymphoma resistance to ibrutinib
Aug 08, 2014
Genomic analyses of tumor and healthy tissue from patients with mantle cell lymphomas that fail to respond to treatment with the anticancer drug ibrutinib (Imbruvica) or initially respond but then stop responding and progress, ...
Study identifies potential drug combination for mantle cell lymphoma and chronic lymphocytic leukemia
Sep 23, 2014
Using the molecularly targeted drug ibrutinib (Imbruvica) together with the investigational anticancer agent ABT-199 may improve outcomes for patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL), ...
Funding to investigate an alternative to chemotherapy
Nov 26, 2014
Professor Simon Rule, Professor in Haematology at Plymouth University Peninsula Schools of Medicine and Dentistry and Consultant Haematologist at Plymouth Hospitals NHS Trust, has been awarded a significant grant by Cancer ...
Tiny mutation triggers drug resistance for patients with one type of leukemia
May 28, 2014
A multi-institutional team of researchers has pinpointed exactly what goes wrong when chronic lymphocytic leukemia (CLL) patients develop resistance to ibrutinib, a highly effective, precisely targeted anti-cancer ...
Experimental drug combination selectively destroys lymphoma cells
Feb 06, 2013
Laboratory experiments conducted by scientists at Virginia Commonwealth University Massey Cancer Center suggest that a novel combination of the drugs ibrutinib and bortezomib could potentially be an effective ...
Recommended for you
Short-term use of hormone replacement therapy associated with increased ovarian cancer risk
4 hours ago
Taking hormone replacement therapy (HRT) for the menopause, even for just a few years, is associated with a significantly increased risk of developing the two most common types of ovarian cancer, according to a detailed re-analysis ...
New research shows possibility of cure for HPV positive throat cancer patients
4 hours ago
Patients with cancer of the throat caused by the Human Papilloma virus (HPV+) have a better prognosis than those who are negative for the virus (HPV-). Now, for the first time, researchers have shown with convincing evidence ...
New radiotracer helps avoid neck dissection in patients with early head and neck cancer
4 hours ago
The discovery that the identification and biopsy of the first lymph node to which a cancer spreads (the sentinel node) can lead to more accurate diagnosis and treatment has revolutionised the management of breast cancer. ...
Mammography rates down since 2009 USPSTF guidelines
13 hours ago
(HealthDay)—Since the publication of the U.S. Preventive Services Task Force guidelines for mammography in 2009, there has been a decrease in mammography rates among white, Hispanic, and Asian women, according ...
Two cell-signaling molecules found to suppress the spread of melanoma
19 hours ago
In what is believed to be the largest epigenetic analysis to date of cell-signaling molecules in early-stage melanoma, researchers at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center have identified ...
Fatal cancer found among Southern Nevada residents likely caused by asbestos in nature
19 hours ago
Southern Nevada counties that include Las Vegas show high proportions of women and younger residents coming down with a rare and aggressive cancer more commonly found in older men occupationally exposed to ...
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here to reset your password.
Sign in to get notified via email when new comments are made.
© Medical Xpress 2011-2014, Science X network
Genomic analyses of tumor and healthy tissue from patients with mantle cell lymphomas that fail to respond to treatment with the anticancer drug ibrutinib (Imbruvica) or initially respond but then stop responding and progress, provided explanations for these two types of drug resistance and suggested ways to overcome them in the clinic, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.
"Ibrutinib, a drug that targets a protein called BTK, shows unprecedented clinical activity against mantle cell lymphoma," said Selina Chen-Kiang, PhD, professor of pathology and laboratory medicine and professor of microbiology and immunology at Weill Cornell Medical College, New York. "However, the drug doesn't work for about 32 percent of patients, and their lymphomas are said to have primary resistance to ibrutinib. We are also learning that most patients whose lymphomas respond to ibrutinib eventually relapse because their tumors acquire resistance to the drug.
"The knowledge that we gained from longitudinal RNA and genomic sequencing of mantle cell lymphomas with primary and acquired resistance to ibrutinib allowed us to identify rational drug combinations that may overcome resistance in these two settings," continued Chen-Kiang. "We recently opened a clinical trial to test one of these combinations, the selective CDK4/6 inhibitor palbociclib and ibrutinib [NCT02159755]."
"Unfortunately, only a subset of mantle cell lymphoma patients respond to ibrutinib and those who do respond eventually relapse," said Lewis C. Cantley, PhD, who directs the Sandra and Edward Meyer Cancer Center at Weill Cornell. "In this paper, the authors conducted a longitudinal study to investigate molecular events that occur during treatment with ibrutinib and identified a mutation in the target of ibrutinib, BTK, that confers resistance to the drug. They also discovered that high levels of PI3K-AKT and CDK4 signaling could explain innate resistance to ibrutinib and showed in ex-vivo studies that a combination of a CDK4 inhibitor and a PI3K inhibitor might be effective for treating patients who do not respond to ibrutinib.
"This study not only suggests new approaches for treating mantle cell lymphoma but also has implications for treatment of other B cell lymphomas, such as CLL, and a diverse group of non-Hodgkin lymphomas," continued Cantley, who is also co-editor-in-chief of Cancer Discovery. Cantley recused himself from the peer review of the study.
Chen-Kiang and colleagues used whole-exome and whole-transcriptome analysis of five serial biopsies from a patient who had mantle cell lymphoma that initially responded to ibrutinib before progressing to identify reasons why mantle cell lymphomas acquire resistance to ibrutinib. After comparing these data with results from analysis of healthy tissues from the same patient, the researchers found that a mutation in BTK, the C481S mutation, appeared at relapse. The same mutation was detected at relapse in a second patient who had mantle cell lymphoma with acquired resistance to ibrutinib but not in any patients with primary resistance to the drug.
Further analyses revealed the consequences of the relapse-specific BTK C481S mutation, including activation of the PI3K and CDK4 signaling pathways, which promote cell survival and proliferation. Blocking CDK4 with the investigational anticancer drug palbociclib made ibrutinib-resistant lymphoma cells carrying the BTK C481S mutation sensitive to investigational drugs that inhibit PI3K. In addition, palbociclib made ibrutinib-resistant lymphoma cells harboring normal BTK sensitive to both ibrutinib and investigational drugs that inhibit PI3K.
"We are very excited to have generated data that we have been able to put together in a way that may be meaningful for patients," said Chen-Kiang. "It is also exciting because CDK4 is a new kind of drug target; it controls the cell cycle, which is a central cancer pathway. As such, it is not just important for mantle cell lymphoma but for many forms of cancer."
This study was supported by funds from the Lymphoma Research Foundation, the Lymphoma Foundation, the Cancer Research and Treatment Fund, the Leukemia and Lymphoma Society, and the National Cancer Institute. Chen-Kiang declares no conflicts of interest.
Explore further: Study identifies rational drug combinations that may overcome mantle cell lymphoma resistance to ibrutinib
Medical Xpress on facebook
Related Stories
Study identifies rational drug combinations that may overcome mantle cell lymphoma resistance to ibrutinib
Aug 08, 2014
Genomic analyses of tumor and healthy tissue from patients with mantle cell lymphomas that fail to respond to treatment with the anticancer drug ibrutinib (Imbruvica) or initially respond but then stop responding and progress, ...
Study identifies potential drug combination for mantle cell lymphoma and chronic lymphocytic leukemia
Sep 23, 2014
Using the molecularly targeted drug ibrutinib (Imbruvica) together with the investigational anticancer agent ABT-199 may improve outcomes for patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL), ...
Funding to investigate an alternative to chemotherapy
Nov 26, 2014
Professor Simon Rule, Professor in Haematology at Plymouth University Peninsula Schools of Medicine and Dentistry and Consultant Haematologist at Plymouth Hospitals NHS Trust, has been awarded a significant grant by Cancer ...
Tiny mutation triggers drug resistance for patients with one type of leukemia
May 28, 2014
A multi-institutional team of researchers has pinpointed exactly what goes wrong when chronic lymphocytic leukemia (CLL) patients develop resistance to ibrutinib, a highly effective, precisely targeted anti-cancer ...
Experimental drug combination selectively destroys lymphoma cells
Feb 06, 2013
Laboratory experiments conducted by scientists at Virginia Commonwealth University Massey Cancer Center suggest that a novel combination of the drugs ibrutinib and bortezomib could potentially be an effective ...
Recommended for you
Short-term use of hormone replacement therapy associated with increased ovarian cancer risk
4 hours ago
Taking hormone replacement therapy (HRT) for the menopause, even for just a few years, is associated with a significantly increased risk of developing the two most common types of ovarian cancer, according to a detailed re-analysis ...
New research shows possibility of cure for HPV positive throat cancer patients
4 hours ago
Patients with cancer of the throat caused by the Human Papilloma virus (HPV+) have a better prognosis than those who are negative for the virus (HPV-). Now, for the first time, researchers have shown with convincing evidence ...
New radiotracer helps avoid neck dissection in patients with early head and neck cancer
4 hours ago
The discovery that the identification and biopsy of the first lymph node to which a cancer spreads (the sentinel node) can lead to more accurate diagnosis and treatment has revolutionised the management of breast cancer. ...
Mammography rates down since 2009 USPSTF guidelines
13 hours ago
(HealthDay)—Since the publication of the U.S. Preventive Services Task Force guidelines for mammography in 2009, there has been a decrease in mammography rates among white, Hispanic, and Asian women, according ...
Two cell-signaling molecules found to suppress the spread of melanoma
19 hours ago
In what is believed to be the largest epigenetic analysis to date of cell-signaling molecules in early-stage melanoma, researchers at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center have identified ...
Fatal cancer found among Southern Nevada residents likely caused by asbestos in nature
19 hours ago
Southern Nevada counties that include Las Vegas show high proportions of women and younger residents coming down with a rare and aggressive cancer more commonly found in older men occupationally exposed to ...
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here
to reset your password.
Sign in to get notified via email when new comments are made.
© Medical Xpress 2011-2014, Science X network
0 comments:
Post a Comment